Research programme: telomere capping inhibitors - Gemin X

Drug Profile

Research programme: telomere capping inhibitors - Gemin X

Latest Information Update: 27 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gemin X Biotechnologies
  • Developer Exelgen; Gemin X Biotechnologies
  • Class Small molecules
  • Mechanism of Action Heterogeneous nuclear ribonucleoprotein group A B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 Nov 2007 Tripos Discovery Research is now called Exelgen
  • 10 Aug 2007 Lead compound series discovered
  • 25 Jan 2006 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top